Evidence map›Paper›PMID 32751779›Full record

ArticleBiomedicines2020

The First Human Clinical Trial on the Skin Depigmentation Efficacy of Glycinamide Hydrochloride.

Yong Chool Boo, Da Jung Jo, Chang Min Oh, Shin Young Lee, Young Mi Kim

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yong Chool BooDepartment of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Korea.ORCID 0000-0001-9895-2066
Da Jung JoDermapro Skin Research Center, Dermapro Ltd., Seoul 06684, Korea.
Chang Min OhDepartment of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Korea.
Shin Young LeeRuby Crown Co., Ltd., Suite 505, Korea Mediventure Center, 76 Dongnae-ro, Dong-gu, Daegu 41061, Korea.
Young Mi KimRuby Crown Co., Ltd., Suite 505, Korea Mediventure Center, 76 Dongnae-ro, Dong-gu, Daegu 41061, Korea.
Kyungpook National University · KR

Funding

Ministry of Small and Medium-Sized Enterprises and Startups S2643749National Research Foundation of Korea 2019R1I1A2A01045132
6 · The paper itself

Abstract

A previous study identified certain low molecular anti-melanogenic peptides that share a common sequence with α-melanocyte stimulating hormone (MSH) and end with a glycinamide moiety. Glycinamide itself also showed anti-melanogenic activity in cell-based assays, but neither glycine nor acetyl glycinamide were active, which indicated a special structure and activity relationship. The aim of this study was to examine the skin depigmentation efficacy of glycinamide hydrochloride in human subjects. The primary skin irritation potential of glycinamide hydrochloride was evaluated by patch testing in 30 human subjects. The skin depigmentation efficacy of glycinamide hydrochloride was evaluated in a double-blinded clinical test in 21 human subjects. The test product and a control product were applied to designated sites on the right or left side of the face twice daily for eight weeks. Skin color parameters, i.e., the melanin index, the L* value (representing skin lightness), a* value (redness), and b* value (yellowness) were measured using instruments. The individual topology angle (ITA

Indexed as

depigmentingglycinamide hydrochloridemelaninpeptidepigmentationskin lighteningwhitening

Identifiers

PMID32751779
PMCPMC7460399
OpenAlexW3045575796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.